Literature DB >> 29420981

Prostate MR Imaging for Posttreatment Evaluation and Recurrence.

Sonia Gaur1, Baris Turkbey2.   

Abstract

Prostate multiparametric MR imaging (mpMRI) plays an important role in local evaluation after treatment of prostate cancer. After radical prostatectomy, radiation therapy, and focal therapy, mpMRI can be used to visualize normal post-treatment changes and to diagnose locally recurrent disease. An understanding of the various treatments and expected changes is essential for complete and accurate post-treatment mpMRI interpretation. Published by Elsevier Inc.

Entities:  

Keywords:  Focal therapy; Prostate cancer; Radiation therapy; Radical prostatectomy; Recurrence; mpMRI

Mesh：

Year:  2017        PMID： 29420981      PMCID： PMC5844499          DOI： 10.1016/j.rcl.2017.10.008

Source DB:  PubMed          Journal:  Radiol Clin North Am        ISSN： 0033-8389            Impact factor:   2.303


  86 in total

1.  Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis.

Authors:  Eric M Horwitz; Lawrence B Levy; Howard D Thames; Patrick A Kupelian; Alvaro A Martinez; Jeffrey M Michalski; Thomas M Pisansky; Howard M Sandler; William U Shipley; Michael J Zelefsky; Anthony L Zietman; Deborah A Kuban
Journal:  Cancer       Date:  2006-10-01       Impact factor: 6.860

2.  Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging.

Authors:  Stefano Cirillo; Massimo Petracchini; Lorenza Scotti; Teresa Gallo; Annalisa Macera; Maria Cristina Bona; Cinzia Ortega; Pietro Gabriele; Daniele Regge
Journal:  Eur Radiol       Date:  2008-09-30       Impact factor: 5.315

3.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.

Authors:  Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin
Journal:  JAMA       Date:  2005-07-27       Impact factor: 56.272

4.  Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry.

Authors:  John F Ward; J Stephen Jones
Journal:  BJU Int       Date:  2011-10-28       Impact factor: 5.588

Review 5.  Cancer treatment and survivorship statistics, 2012.

Authors:  Rebecca Siegel; Carol DeSantis; Katherine Virgo; Kevin Stein; Angela Mariotto; Tenbroeck Smith; Dexter Cooper; Ted Gansler; Catherine Lerro; Stacey Fedewa; Chunchieh Lin; Corinne Leach; Rachel Spillers Cannady; Hyunsoon Cho; Steve Scoppa; Mark Hachey; Rebecca Kirch; Ahmedin Jemal; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2012-06-14       Impact factor: 508.702

6.  Prostate-specific antigen (PSA) bounce and other fluctuations: which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy.

Authors:  Tom Pickles
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-01-10       Impact factor: 7.038

7.  T2-Weighted endorectal magnetic resonance imaging of prostate cancer after external beam radiation therapy.

Authors:  Antonio C Westphalen; John Kurhanewicz; Rui M G Cunha; I-Chow Hsu; John Kornak; Shoujun Zhao; Fergus V Coakley
Journal:  Int Braz J Urol       Date:  2009 Mar-Apr       Impact factor: 1.541

8.  Image guided photothermal focal therapy for localized prostate cancer: phase I trial.

Authors:  U Lindner; R A Weersink; M A Haider; M R Gertner; S R H Davidson; M Atri; B C Wilson; A Fenster; J Trachtenberg
Journal:  J Urol       Date:  2009-08-14       Impact factor: 7.450

9.  Focal cryosurgery followed by penile rehabilitation as primary treatment for localized prostate cancer: initial results.

Authors:  David S Ellis; Theodore B Manny; John C Rewcastle
Journal:  Urology       Date:  2007-12       Impact factor: 2.649

Review 10.  Functional and molecular imaging of localized and recurrent prostate cancer.

Authors:  Kinzya Grant; Maria L Lindenberg; Haytham Shebel; Yuxi Pang; Harsh K Agarwal; Marcelino Bernardo; Karen A Kurdziel; Baris Turkbey; Peter L Choyke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-07       Impact factor: 9.236
View more
  11 in total

1.  Evaluating Biochemically Recurrent Prostate Cancer: Histologic Validation of 18F-DCFPyL PET/CT with Comparison to Multiparametric MRI.

Authors:  Liza Lindenberg; Esther Mena; Baris Turkbey; Joanna H Shih; Sarah E Reese; Stephanie A Harmon; Ilhan Lim; Frank Lin; Anita Ton; Yolanda L McKinney; Philip Eclarinal; Deborah E Citrin; William Dahut; Ravi Madan; Bradford J Wood; Venkatesh Krishnasamy; Richard Chang; Elliot Levy; Peter Pinto; Janet F Eary; Peter L Choyke
Journal:  Radiology       Date:  2020-07-07       Impact factor: 11.105

2.  Diagnostic value of retrospectively fused 64CuCl2 PET/MRI in biochemical relapse of prostate cancer: comparison with fused 18F-Choline PET/MRI, 64CuCl2 PET/CT, 18F-Choline PET/CT, and mpMRI.

Authors:  Francesco Paparo; Alice Peirano; João Matos; Lorenzo Bacigalupo; Umberto Rossi; Ilaria Mussetto; Gianluca Bottoni; Martina Ugolini; Carlo Introini; Filippo Grillo Ruggieri; Gian Andrea Rollandi; Arnoldo Piccardo
Journal:  Abdom Radiol (NY)       Date:  2020-11

3.  Prospective Evaluation of 18F-DCFPyL PET/CT in Detection of High-Risk Localized Prostate Cancer: Comparison With mpMRI.

Authors:  Sonia Gaur; Esther Mena; Stephanie A Harmon; Maria L Lindenberg; Stephen Adler; Anita T Ton; Joanna H Shih; Sherif Mehralivand; Maria J Merino; Bradford J Wood; Peter A Pinto; Ronnie C Mease; Martin G Pomper; Peter L Choyke; Baris Turkbey
Journal:  AJR Am J Roentgenol       Date:  2020-07-08       Impact factor: 3.959

4.  Detection of failure patterns using advanced imaging in patients with biochemical recurrence following low-dose-rate brachytherapy for prostate cancer.

Authors:  Kilian E Salerno; Baris Turkbey; Liza Lindenberg; Esther Mena; Erica E Schott; Alexandra K Brennan; Soumyajit Roy; Uma Shankavaram; Krishnan Patel; Theresa Cooley-Zgela; Yolanda McKinney; Bradford J Wood; Peter A Pinto; Peter Choyke; Deborah E Citrin
Journal:  Brachytherapy       Date:  2022-05-04       Impact factor: 2.441

5.  Use and Outcomes of SBRT for Early Stage NSCLC Without Pathologic Confirmation in the Veterans Health Care Administration.

Authors:  Joel R Wilkie; Rachel Lipson; Matthew C Johnson; Christina Williams; Drew Moghanaki; David Elliott; Dawn Owen; Namratha Atluri; Shruti Jolly; Christina Hunter Chapman
Journal:  Adv Radiat Oncol       Date:  2021-04-20

6.  Successful Stereotactic Body Radiation Therapy for Postbrachytherapy Prostate Recurrence and Penile Bulb Metastasis.

Authors:  Deborah E Citrin; Erica Schott; Kilian Salerno; Holly Ning; Peter A Pinto; Bradford J Wood; Liza Lindenberg; Esther Mena; Baris Turkbey
Journal:  Adv Radiat Oncol       Date:  2021-11-28

Review 7.  Magnetic resonance imaging of the prostate after focal therapy with high-intensity focused ultrasound.

Authors:  Soleen Ghafoor; Daniel Stocker; Olivio F Donati; Hebert Alberto Vargas; Anton S Becker; Borna K Barth; Daniel Eberli
Journal:  Abdom Radiol (NY)       Date:  2020-11

Review 8.  Focal Salvage Treatment of Radiorecurrent Prostate Cancer: A Narrative Review of Current Strategies and Future Perspectives.

Authors:  Marieke van Son; Max Peters; Marinus Moerland; Linda Kerkmeijer; Jan Lagendijk; Jochem van der Voort van Zyp
Journal:  Cancers (Basel)       Date:  2018-12-03       Impact factor: 6.639

Review 9.  Evolution of prostate MRI: from multiparametric standard to less-is-better and different-is better strategies.

Authors:  Rossano Girometti; Lorenzo Cereser; Filippo Bonato; Chiara Zuiani
Journal:  Eur Radiol Exp       Date:  2019-01-28

10.  Detecting recurrent prostate Cancer using multiparametric MRI, influence of PSA and Gleason grade.

Authors:  Aradhana M Venkatesan; Eniola Mudairu-Dawodu; Cihan Duran; R Jason Stafford; Yuanqing Yan; Wei Wei; Vikas Kundra
Journal:  Cancer Imaging       Date:  2021-01-06       Impact factor: 3.909
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.